BioReliance Appoints Executive Chairman to be Interim CEO and Announces Recent Senior Executive... ( ROCKVILLE Md. Oct. 29 /- BioRelia...)

BioReliance Appoints Executive Chairman to be Interim CEO and Announces Recent Senior Executive Additions

Date:10/29/2007

ROCKVILLE, Md., Oct. 29 /PRNewswire/ -- BioReliance Corporation today appointed its Executive Chairman, Charles C. Harwood, Jr., to the additional post of Interim CEO, following the announced resignation of Tim Derrington from the CEO position. In addition, BioReliance announced that three senior executives have joined the company since June: David E. Onions, Ph.D., as Chief Scientific Officer, David S. Walker as Chief Financial Officer, and Darryl L. Goss as Vice President of Global Process Excellence.

BioReliance is a portfolio company of Avista Capital Partners and was purchased in April 2007 from Invitrogen Corporation. Charles Harwood comments, "While Tim Derrington's personal decision to leave BioReliance was not anticipated at the time of the acquisition, the Board does not believe it will affect the timetable for strengthening the senior executive team and setting a clear course for BioReliance as a stand-alone company."

In addition to serving as Executive Chairman of BioReliance, Mr. Harwood serves on the boards of several other healthcare companies, including ATCC and RadPharm, Inc., and recently formalized a relationship with Avista to support their healthcare team as a Healthcare Industry Advisor. From 2002 to 2006, Mr. Harwood served as President and CEO of Focus Diagnostics, Inc., a specialty diagnostics company offering advanced laboratory testing services and diagnostic products. Previously, from 1993 to 2001, Mr. Harwood held several positions, including Chief Financial Officer and SVP of Venture Development, at Covance, Inc., one of the largest drug development services companies. Mr. Harwood began his healthcare career in the medical equipment field working for the Medical Products Group of Hewlett-Packard Company. He received an MBA from Harvard Business School and a Bachelor of Arts from Stanford University.

David Onions is the Chief Scientific Officer and a member of the Board of BioReliance. He was formerly Chief Medic
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Where Burnt Out Executives De-stress in Natures Lap
2. Asian Business Executives Urged to Be Eco-friendly
3. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
4. Bruce Vladeck Will Hold Fort (interim) of UMDNJ
5. Interim WHO Chief Confirms No radical changes in WHO
6. Interim OPD saves the day for patients
7. PM announces a new health care order for India
8. Ramdoss Announces Introduction of RCH-II
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Tibet Announces the Dalai Lama’s Tour of South Americ

Post Your Comments:

BioReliance Appoints Executive Chairman to be Interim CEO and Announces Recent Senior Executive...( ROCKVILLE Md. Oct. 29 /- BioRelia...),Health